Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect

Purpose: Combining siRNA and other chemotherapeutic agents into one nanocarrier can overcome the multidrug resistance (MDR) phenomenon by synergistically MDR relative genes silencing and elevated chemotherapeutic activity. Most of these systems are typically fabricated through complicated procedures, which involves materials preparation, drug loading and modifications. Herein, the purpose of this study is to develop a new and fast co-delivery system of siRNA and doxorubicin for potentially synergistic cancer treatment. Methods: The co-delivery system is constructed conveniently by a stable complex consisting of doxorubicin bound to siRNA via intercalation firstly, followed by interacting with (3-Aminopropyl)triethoxysilane (APTES) electrostatically and Tetraethyl orthosilicate (TEOS) co-condensed, and the characterizations of the resultant nanocarrier are also investigated. Furthermore, this study evaluates the synergistic anti-cancer efficacy in MCF-7/MDR cells after treatment of siRNA and doxorubicin ‘two in one’ nanocarriers. Results: We establish a new and fast method to craft a co-delivery system of siRNA and doxorubicin with controllable and nearly uniform size, and the entire fabrication process only costs in about 10 minutes. The resultant co-delivery system presents high loading capacities of siRNA and doxorubicin, and the encapsulated doxorubicin plays a pH-responsive control release. Further, biological functionality tests of the synthesized co-delivery nanocarriers show high inhibition of P-gp protein encoded by MDR-1 gene in MCF-7/MDR cells (a variant of human breast cancer cell line with drug resistance) after transfection of these nanocarriers carrying MDR-1 siRNA and doxorubicin simultaneously, which sensitize the MCF-7/MDR cells to doxorubicin, overall leading to improved cell suppression. Conclusion: Collectively, this co-delivery system not only serves as potent therapeutics for synergistic cancer therapy, it also may facilitate the bench-to-bedside translation of combinatorial delivery system as a robust drug nanocarrier by allowing for fabricating a simply and fast nanocarrier for co-delivery of siRNA and doxorubicin with predictable high production rate.

[1]  Wei Pan,et al.  Reversing Multidrug Resistance by Multiplexed Gene Silencing for Enhanced Breast Cancer Chemotherapy. , 2018, ACS applied materials & interfaces.

[2]  Bai Yang,et al.  Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment , 2017, International journal of nanomedicine.

[3]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[4]  Hyundong Yoo,et al.  Multivalent Aptamer-RNA Conjugates for Simple and Efficient Delivery of Doxorubicin/siRNA into Multidrug-Resistant Cells. , 2017, Macromolecular bioscience.

[5]  Jonathan Rasmussen,et al.  Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy. , 2017, ACS nano.

[6]  Y. Assaraf,et al.  Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance. , 2017, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  Akshay Jain,et al.  Comparison of Avidin, Neutravidin, and Streptavidin as Nanocarriers for Efficient siRNA Delivery. , 2017, Molecular pharmaceutics.

[8]  K. Kataoka,et al.  Recent progress in development of siRNA delivery vehicles for cancer therapy. , 2016, Advanced drug delivery reviews.

[9]  R. Shukla,et al.  Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[10]  H. Gu,et al.  Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy , 2015, International journal of nanomedicine.

[11]  H. Gu,et al.  Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier. , 2014, Biomaterials.

[12]  Y. Yao,et al.  Template-assisted self-assembly: alignment, placement, and arrangement of two-dimensional mesostructured DNA-silica platelets. , 2013, Angewandte Chemie.

[13]  Daniel Anderson,et al.  Delivery materials for siRNA therapeutics. , 2013, Nature materials.

[14]  Chen Jiang,et al.  Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. , 2013, ACS nano.

[15]  Tian Xia,et al.  Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. , 2013, ACS nano.

[16]  Nicholas A Peppas,et al.  Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. , 2012, Nano today.

[17]  Linlin Li,et al.  Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery , 2012, Advanced materials.

[18]  S. Che,et al.  DNA–Silica Mineralization: The Formation of Exceptional Two Dimensional-Square p4mm Symmetry by a Structural Transformation , 2012 .

[19]  Afsaneh Lavasanifar,et al.  Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. , 2011, ACS nano.

[20]  Chen Jiang,et al.  Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. , 2011, Biomaterials.

[21]  Zongxi Li,et al.  Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. , 2010, Small.

[22]  Cui Tang,et al.  Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. , 2010, Biomaterials.

[23]  Min Zhang,et al.  Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. , 2009, Small.

[24]  S. Che,et al.  DNA transcription into diverse porous silicas by a co-structure directing route: chiral, ring and ordered nanochannel arrays. , 2009, Chemical communications.

[25]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[26]  Robert Langer,et al.  An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. , 2006, Angewandte Chemie.

[27]  O. Terasaki,et al.  A novel anionic surfactant templating route for synthesizing mesoporous silica with unique structure , 2003, Nature materials.

[28]  F. Caruso,et al.  Super-Resolution Imaging of Proton Sponge-Triggered Rupture of Endosomes and Cytosolic Release of siRNA , 2019 .

[29]  Akshay Jain,et al.  Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[30]  Kwangmeyung Kim,et al.  Synergistic antitumor e ff ects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles , 2017 .